# Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

> **NCT06827782** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 42 (estimated)

## Conditions studied

- Refractory/Recurrent Central Nervous System Lymphoma

## Interventions

- **BIOLOGICAL:** anti-CD19 CAR-NK cells

## Key facts

- **NCT ID:** NCT06827782
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-03-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06827782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06827782, "Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06827782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*